Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia

Highlights • Study documents evidence regarding HCV treatment access in Eastern Europe and Asia. • PWID carry a significant relative HCV burden of disease, ranging from 2.7% to 40.4%. • Yearly treatment uptake was below 1% for the general population and PWID. • National policy plans did not include...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The International journal of drug policy 2015-11, Vol.26 (11), p.1081-1087
Hauptverfasser:	Luhmann, Niklas, Champagnat, Julie, Golovin, Sergey, Maistat, Ludmila, Agustian, Edo, Inaridze, Ina, Myint, Wai Moe, Butsashvili, Maia, Bouscaillou, Julie
Format:	Artikel
Sprache:	eng
Schlagworte:	Asia Developing Countries Disease burden Drug policy Drug use Epidemics Europe, Eastern Health care access Health Services Accessibility Hepatitis Hepatitis C Hepatitis C - epidemiology Hepatitis C - etiology Hepatitis C - therapy Hepatitis C virus Humans Injections Internal Medicine Medical Education Medical treatment People who inject drugs Prevalence Substance Abuse, Intravenous - complications Substance Abuse, Intravenous - epidemiology Systematic review Treatment access
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Study documents evidence regarding HCV treatment access in Eastern Europe and Asia. • PWID carry a significant relative HCV burden of disease, ranging from 2.7% to 40.4%. • Yearly treatment uptake was below 1% for the general population and PWID. • National policy plans did not include specific and relevant strategies regarding PWID. • Study shows an urgent need for improvement of HCV treatment access in LMICs.
ISSN:	0955-3959 1873-4758
DOI:	10.1016/j.drugpo.2015.07.016